NEW YORK – Although there are well-established treatments for many of the cancers that occur in children, there are cases where reliable treatments do not exist, particularly for pediatric cancers that recur.
Those difficult-to-treat cases are among those being tackled through KidsCanSeq, a Texas-based genomics-centered pediatric oncology study. The effort was launched in 2018 with $2.8 million in funding from the second phase of the National Human Genome Research Institute's Clinical Sequencing Evidence-Generating Research Consortium, known as CSER2.